- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06084637
Comparison Between Intra-articular Infiltrations of PRP, MFAT, and PRP-MFAT in the Treatment of Symptomatic Knee Osteoarthritis. (MICROPREP3)
Randomized Control Trial Comparison Between Intra-articular Infiltrations of PRP, MFAT, and PRP-MFAT in the Treatment of Symptomatic Knee Osteoarthritis.
This research protocol evaluate the efficacity of intra-articular injections of autologous microfat associated with a preparation of autologous PRP, in symptomatic, resistant to first-line medical treatment, degenerative or post-traumatic cartilage lesions of the knee.
The primary objective of this study is to show the superiority of intra-articular injection of autologous microfat combined with autologous PRP preparation compared to injection of microfat or PRP used alone, on the KOOS score at 6 months.
Study Overview
Status
Conditions
Detailed Description
Osteoarthritis is the most widespread joint disease in the world, and one of the most frequent causes of pain and functional disability in Western countries. The incidence of cartilage lesions is constantly on the rise, due to the ageing of the population and the traumas associated with the development of sporting activities.
Recently, the emergence of biotherapies in orthopaedics has led to the development of intra-articular injections of autologous platelet-rich plasma (PRP). Their use has been widespread since 2010, based on the demonstration that platelet-enriched plasma, a concentrate of growth factors, can stimulate cartilage regeneration in vitro and in vivo in preclinical models (Saito, Schmidt, Qi, Tchetina). In addition, PRP administration methods can be optimized: since it is a liquid preparation (platelet suspension), administering it within an interface tissue limits its diffusion and potentiates its trophic effect on the injured cartilage site. Adipose tissue represents the most relevant tissue of interest, as it is a stem cell-rich support tissue with full therapeutic potential, and is easily accessible. Thus, a sample of autologous "microfat" (adipose tissue containing small fat lobules and stem cells, harvested under local anaesthetic by manual liposuction using specific fine sampling cannulas) co-administered at the level of the synovial capsule, could play the role of fluid trophic matrix to the PRP.
The hypothesis of this project is that the standardized injection of an innovative treatment (microgrease and autologous PRP dose) can defer the need for knee arthroplasty in patients with gonarthrosis resistant to first-line medical treatment. The investigators propose to carry out a clinical study in patients with chondral knee lesions resistant to first-line medical treatment, evaluating the benefit during follow-up of treatment with intra-articular injections of microfat and a standardized preparation of autologous PRP or the combination of the 2.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Alexandra GIULIANI
- Phone Number: 0491382870
- Email: alexandra.giuliani@ap-hm.fr
Study Contact Backup
- Name: Alexandre ROCHWERGER, Pr
- Phone Number: 04 91 96 63 00
- Email: richardalexandre.rochwerger@ap-hm.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients of both gender, between 20 and 75 year-old.
- Symptomatics degenerativ or post traumatic chondropathy, on at least one of the 3 knee compartments ICRS grade 2, 3 or 4 with VAS>4 and failure of well-conducted medical treatment for at least 1 year (palliative analgesics adapted to the pain, AINS, rehabilitation by a physiotherapist, injections intra-articulaires de corticoïdes et/ou d'acide hyaluronique)
- Varus or valgus less than or equal to 5°.
- BMI greater than 20 (in order to have sufficient fatty tissue)
- Informed consent signed by the patient
- HB > 10g/dl
- Negative beta-HCG at inclusion and effective contraception for patients of childbearing age, for 1 month.
- Beneficiaries of or affiliated to a social security system
Exclusion Criteria:
- Contraindications to MRI : ocular foreign bodies, pacemaker, neurostimulator, cochlear implant, vascular clips, metallic heart valve
- Body mass index (BMI) of less than 20 kg/m2 not allowig to obtain a sufficient quantity of adipose tissue.
- Thrombocytopenia < 150 G/L
- Thrombocytosis > 450 G/L
- Known thrombopathy
- TP=> PR < 70%.
- TCA=> APR > 1.20s
- Anemia HB < 10g/dl
- Positive markers for the following active infectious diseases: HIV 1 and HIV 2 human immunodeficiency virus infection; HTLV I and II virus infection; Hepatitis B virus infection; Hepatitis C virus infection; Syphilis causative agent infection.
- Use of antiplatelet agents, aspirin, anti-vitamin K drugs for less than 15 days.
- Chronic treatment with oral corticosteroids or the use of such treatment less than 2 weeks prior to inclusion
- Intra-articular corticosteroid injection less than 2 months prior to inclusion
- Intra-articular injection of hyaluronic acid less than 2 months prior to inclusion
- Non-steroidal anti-inflammatory drugs less than 15 days prior to inclusion
- Recent fever or infection (bacterial or viral) less than one month old
- Autoimmune diseases
- Inflammatory arthritis
- Immune deficiency
- Ongoing or chronic infectious diseases (viral or bacterial)
- T Malignant tumours or history of malignant tumours less than 5 years prior to inclusion
- Pregnant or lactating women
- Adults protected by law (guardianship or curatorship)
- Patient participating simultaneously in another research project involving the human person
- Minors
- Persons residing in a health or social institution
- Persons in emergency situations
- Persons deprived of liberty
- Persons not covered by the French social security scheme
- Contraindication to local anesthesia and/or surgery
- Allergy to local anesthetics
- Inmates
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: autologous microfat (MG)
Patient will be hospitalized in outpatient surgery.
A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon.
Then, biological products will be immediately prepared, and a preparation of autologous MG will be injected intra-articularly by th same surgeon.
|
A preparation of autologous microfat (5mL) will be injected intra-articularly.
|
Experimental: Platelet-rich plasma (PRP)
Patient will be hospitalized in outpatient surgery.
A blood sample will be collected and a lipoaspiration will be performed under local anesthesia during the same operation by the nurses and the surgeon.
Then, biological products will be immediately prepared, and a preparation of autologous PRP will be injected intra-articularly by th same surgeon.
|
A preparation of autologous platelet-rich plasma (5mL) will be injected intra-articularly.
|
Experimental: Microfat autologous-Platelet-rich plasma (MG-PRP)
Patient will be hospitalized in outpatient surgery.
A blood sample will be collected and a lipoaspiration will be performed for the preparation during the same operation by the nurses and the surgeon.
Then, biological products will be immediately prepared, and autologous microfat associated with a preparation of autologous PRP will be injected intra-articularly by th same surgeon.
|
A preparation of autologous platelet-rich plasma (5mL) and autologous microfat (5mL) will be injected intra-articularly.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
KOOS score at 6 months
Time Frame: 6 months
|
KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis.
It is percentage from 0 to 100.
0 represents extreme problems and 100 represents no problem.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain at 1 month
Time Frame: 1 month
|
Pain will assassed by a visual anatomy scale from 0 (no pain) to 10 (pain as bad as it could possibly be)
|
1 month
|
Pain at 3 months
Time Frame: 3 months
|
Pain will assassed by a visual anatomy scale from 0 (no pain) to 10 (pain as bad as it could possibly be)
|
3 months
|
Pain at 12 months
Time Frame: 12 months
|
Pain will assassed by a visual anatomy scale from 0 (no pain) to 10 (pain as bad as it could possibly be)
|
12 months
|
KOOS score at 1 month
Time Frame: 1 month
|
KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis.
It is percentage from 0 to 100.
0 represents extreme problems and 100 represents no problem.
|
1 month
|
KOOS score at 3 months
Time Frame: 3 months
|
KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis.
It is percentage from 0 to 100.
0 represents extreme problems and 100 represents no problem.
|
3 months
|
KOOS score at 12 months
Time Frame: 12 months
|
KOOS assesses the short- and long-term consequences of knee injuries, as well as the consequences of primary osteoarthritis.
It is percentage from 0 to 100.
0 represents extreme problems and 100 represents no problem.
|
12 months
|
Proportion of treatment failures
Time Frame: 12 months
|
Patients are defined as treatment failures if, during the follow-up period, they undergo one of the following procedures on the treated knee, in the absence of intercurrent events: new injection (whatever the product injected), arthroscopy, arthroplasty, etc.
|
12 months
|
Proportion of arthroplasties not performed in arthroplasty candidates
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RCAPHM21_0431
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteo Arthritis Knee
-
University of PaviaNot yet recruitingLower Limb Arthroplasty: Effects of a Tele Prehabilitation Program With Indirect Electrostimulation.Osteo Arthritis Knee and Hip | Lower Limb ArthroplastyItaly
-
NHS LothianNot yet recruitingOsteo Arthritis Knee | Arthropathy of Knee | Arthritis KneeUnited Kingdom
-
Science and Research Centre KoperSlovenian Research AgencyCompletedOsteo Arthritis Knee | Knee ArthroplastySlovenia
-
Anchen Pharmaceuticals, IncNovum Pharmaceutical Research ServicesCompletedOsteo Arthritis of the KneeUnited States
-
Royal Infirmary of EdinburghUnknownOsteo Arthritis Knee | Arthroplasty, Replacement, KneeUnited Kingdom
-
Vastra Gotaland RegionActive, not recruiting
-
Smith & Nephew, Inc.Terminated
-
CorinRecruitingOsteo Arthritis Knee | Total Knee Arthroplasty | Total Knee Replacement | Knee DiseaseFrance
-
CorinActive, not recruitingOsteo Arthritis Knee | Total Knee Arthroplasty | Total Knee Replacement | Knee DiseaseFrance
-
Boston UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Not yet recruiting
Clinical Trials on Intra-articular injection of autologous microfat
-
Assistance Publique Hopitaux De MarseilleRecruiting
-
Dalia Salah SaifUnknownRA - Rheumatoid ArthritisEgypt
-
Istanbul UniversityRecruiting
-
Medical University of WarsawUnknownOsteoarthritis | Knee Osteoarthritis | Hip Osteoarthritis | Glenohumeral OsteoarthritisPoland
-
St George's, University of LondonWellcome Trust; Rosetrees TrustUnknownRheumatoid Arthritis | Osteoarthritis, Knee | Psoriatic Arthritis | SpondyloarthritisUnited Kingdom
-
Sisli Hamidiye Etfal Training and Research HospitalCompleted
-
University Hospital TuebingenUnknownJuvenile Idiopathic ArthritisGermany
-
Renew Center, San Antonio, TexasCompletedArthritis, Degenerative
-
University of UtahActive, not recruitingPlatelet-Rich Plasma (PRP) | Knee Osteoarthritis (OA)United States
-
Bioheart, Inc.Anupam Hospital; RegennMed Research and Therapeutics DelhiCompleted